奥氮平5 mg联合三联止吐药用于乳腺癌含蒽环类方案患者的总体疗效与安全性:一项3期、双盲、随机、安慰剂对照试验
这项在日本15家医院开展的3期双盲随机安慰剂对照试验纳入500例I-III期乳腺癌女性患者,评估化疗后在家服用奥氮平5 mg联合三联止吐药对含蒽环类联合环磷酰胺化疗所致恶心呕吐的疗效。奥氮平组总体期完全缓解率58.1%显著高于安慰剂组35.5%(差值22.7%,95%CI 14.0-31.4%,p<0.0001),安全性可接受。
要点
- 化疗后在家服用奥氮平5 mg联合三联止吐药,总体期完全缓解率58.1% vs 安慰剂组35.5%(差值22.7%,95%CI 14.0-31.4%,p<0.0001)。
- 奥氮平组实验药物相关3-4级不良事件包括嗜睡4例(2%)vs 安慰剂组0例,注意力障碍2例(1%)vs 0例,无死亡。
- 基于PRO-CTCAE最常报告的严重或极严重症状为厌食(奥氮平组33例[13%] vs 安慰剂组89例[38%])和便秘(30例[12%] vs 37例[16%])。
核心结论
- 含蒽环类联合环磷酰胺化疗前给予三联止吐药基础上,化疗后服用奥氮平5 mg较安慰剂显著提高总体期化疗所致恶心呕吐的完全缓解率,安全性可接受。
- 作者认为该发现代表化疗所致恶心呕吐管理的实质性进步,并表明奥氮平5 mg可实现安全有效的给药。
研究设计与样本
- 3期、双盲、随机、安慰剂对照试验,在日本15家医院和癌症中心开展。
- 纳入500例20岁及以上、I-III期乳腺癌、ECOG体能状态0-1、计划接受含蒽环类联合环磷酰胺静脉化疗、未接受过化疗或从未接受中高度致吐化疗的女性患者。
- 按1:1随机分配至口服奥氮平5 mg组(n=251)或安慰剂组(n=249),以年龄(≥55岁 vs <55岁)和机构为分层因素,区组大小2。
- 奥氮平或安慰剂于第1天蒽环类联合环磷酰胺给药结束后5小时内、晚餐前在家服用,随后3天晚餐后服用;均在第1天化疗前给予地塞米松9.9 mg静脉注射、帕洛诺司琼0.75 mg静脉注射、阿瑞匹坦125 mg口服,第2、3天追加阿瑞匹坦80 mg,或第1天预处理给予福沙匹坦150 mg静脉注射。
- 主要终点为总体期(蒽环类联合环磷酰胺开始后0-120小时)基于患者日记的完全缓解率,定义为无呕吐且未使用补救止吐药;主要分析采用改良意向治疗人群,安全性分析纳入所有接受任何治疗的患者。
主要发现
- 2020年10月26日至2022年11月2日随机分配500例女性患者,奥氮平组251例、安慰剂组249例;入组时中位年龄奥氮平组52岁(IQR 45-60),安慰剂组51岁(IQR 46-60);中位随访168小时(IQR 168-168)。
- 480例(奥氮平组246例、安慰剂组234例)接受至少一剂研究药物并纳入疗效分析;奥氮平组总体期完全缓解率58.1%(n=143)显著高于安慰剂组35.5%(n=83),差值22.7%(95%CI 14.0-31.4%,p<0.0001)。
- 基于PRO-CTCAE v1.0最常报告的严重或极严重症状为厌食(奥氮平组246例中33例[13%] vs 安慰剂组235例中89例[38%])和便秘(30例[12%] vs 37例[16%])。
- 严重或极严重注意力障碍在奥氮平组246例中报告25例(10%),安慰剂组235例中报告34例(14%)。
- 实验药物相关CTCAE v5.0 3-4级不良事件包括嗜睡(奥氮平组246例中4例[2%] vs 安慰剂组235例中0例)和注意力障碍(2例[1%] vs 0例);无死亡。
临床怎么用
- 对于接受含蒽环类联合环磷酰胺门诊化疗的女性乳腺癌患者,可在化疗前三联止吐药基础上,于化疗结束后5小时内、晚餐前在家服用奥氮平5 mg,随后3天晚餐后服用,以提高总体期完全缓解率并控制镇静风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of 10 mg olanzapine to the standard triplet antiemetic therapy has shown superiority in controlling chemotherapy-induced nausea and vomiting compared with triplet therapy alone for highly emetogenic chemotherapy, albeit with sedative side-effects. We aimed to investigate if administering 5 mg of olanzapine at home after anthracycline plus cyclophosphamide chemotherapy, rather than before chemotherapy, can maintain efficacy in controlling chemotherapy-induced nausea and vomiting while minimising sedative side-effects and associated risks. METHODS: This was a phase 3, double-blind, randomised, placebo-controlled trial, done in 15 hospitals and cancer centres in Japan. Eligible patients were female adults aged 20 years or older with stage I-III breast cancer and an Eastern Cooperative Oncology Group performance status of 0-1, who were scheduled to receive intravenous anthracycline plus cyclophosphamide-based chemotherapy, and were naive to chemotherapy or had never received moderately to highly emetogenic chemotherapy. Eligible patients were randomly assigned 1:1 to oral olanzapine 5 mg or placebo via the central registration system. Randomisation was performed using blocked stratification, with age (≥55 years vs <55 years) and institution as stratification factors and a block size of two. Allocation was concealed and masking was achieved by using tablets with identical appearance. Treatment was administered at home within 5 h after the end of anthracycline plus cyclophosphamide administration and before the patient's evening meal on day 1 to minimise the risk of sedation during hospital visits and transportation, and on the next 3 days after their evening meal, both with pre-chemotherapeutical application of intravenous dexamethasone 9·9 mg, intravenous palonosetron 0·75 mg, and oral aprepitant 125 mg on day 1 followed by an additional dose of aprepitant 80 mg on days 2 and 3 or intravenous fosaprepitant 150 mg as a premedication on day 1. The primary endpoint was the proportion of patients with a complete response, defined as no vomiting and no rescue medication during the overall phase (0-120 h after the initiation of anthracycline plus cyclophosphamide) based on patient diary. The primary analysis was done by modified intention-to-treat, including all patients who received at least one dose of the study treatment and had at least one efficacy evaluation. Safety was analysed in all patients who received any treatment. This trial was registered with the Japan Registry of Clinical Trials, jRCT1031200134, and is complete. FINDINGS: Between Oct 26, 2020 and Nov 2, 2022, 500 female patients from 15 medical institutions in Japan were randomly assigned to receive olanzapine (n=251) or placebo (n=249). Median age at enrolment was 52 years (IQR 45-60) in the olanzapine group and 51 years (46-60) in the placebo group. Data on gender and race or ethnicity were not collected. The median follow-up was 168 h (IQR 168-168). 480 participants (246 in the olanzapine group and 234 in the placebo group) received at least one dose of study medication and were eligible for the efficacy analysis. The complete response rate in the olanzapine group (58·1%, n=143) was significantly higher than in the placebo group (35·5%, n=83; difference 22·7%, 95% CI 14·0-31·4%; p<0·0001) during the overall phase. The most frequently reported severe or very severe symptoms based on the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) version 1.0 were anorexia (33 [13%] of 246 patients in the olanzapine group vs 89 [38%] of 235 in the placebo group) and constipation (30 [12%] vs 37 [16%]). Severe or very severe concentration impairment was reported in 25 (10%) of 246 patients in the olanzapine group and 34 (14%) of 235 patients in the placebo group. Experimental drug-related grade 3-4 adverse events according to the Common Terminology Criteria for Adverse Events version 5.0 included somnolence (four [2%] of 246 patients in the olanzapine group vs none of 235 in the placebo group), and concentration impairment (two [1%] vs none). There were no deaths. INTERPRETATION: Post-chemotherapy administration of 5 mg olanzapine in combination with triplet antiemetic therapy before anthracycline plus cyclophosphamide-based chemotherapy significantly improved the complete response rate for chemotherapy-induced nausea and vomiting during the overall phase compared with placebo in female patients with breast cancer receiving outpatient chemotherapy, with an acceptable level of safety. The findings represent a substantial advancement in managing chemotherapy-induced nausea and vomiting and provide assurance that the safe and effective administration of olanzapine can be achieved at a dosage of 5 mg. FUNDING: The Capture of Outstanding Clinical Research and Evolution (CORE) project at Juntendo University.
引用
- Saito M, Iihara H, Shimokawa M, et al. Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2025. PMID: 40541214. doi:10.1016/S1470-2045(25)00233-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。